Open AccessPrognostic significance of longitudinal evaluation on egfr mutant ctdna during tki treatment in nsclc
Author(s) -
Ф. В. Моисеенко,
Nikita Volkov,
А. С. Жабина,
M. Stepanova,
N.A. . Rjsev,
В. В. Клименко,
A. Myslik,
E. V. Artemieva,
N. H. Abduloeva,
V.V. Egorenkov,
Vladimir Moiseyenko
Publication year - 2020
Publication title -
praktičeskaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1726-9830
pISSN - 1726-9814
DOI - 10.31917/2104296
Subject(s) - oncology , medicine , adenocarcinoma , lung cancer , clinical trial , tyrosine kinase inhibitor , population , tyrosine kinase , cancer , receptor , environmental health
Detection of EGFR mutations in tumor tissue is the gold standard for prescribing tyrosine kinase inhibitor therapy.However even in the same molecularly defined population effect of the treatment, response duration and survival might differ significantly. We did a prospective clinical trial to assess ctDNA-based EGFR mutations as a prognostic marker for patients with lung adenocarcinoma receiving TKI as first-line treatment.